Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical benefit of glycoprotein IIb/IIIa receptor antagonists in patientswith acute coronary syndrome
Autore:
Haase, KK; Koenig, W;
Indirizzi:
Univ Heidelberg, Klinikum Mannheim gGmbH, Fak Klin Med, Med Klin, Mannheim, Germany Univ Heidelberg Mannheim Germany Klin Med, Med Klin, Mannheim, Germany Univ Ulm, Med Klin, Innere Med Abt 2, Ulm, Germany Univ Ulm Ulm GermanyUniv Ulm, Med Klin, Innere Med Abt 2, Ulm, Germany
Titolo Testata:
PERFUSION
fascicolo: 2, volume: 14, anno: 2001,
pagine: 56 - 60
SICI:
0935-0020(200102)14:2<56:CBOGIR>2.0.ZU;2-W
Fonte:
ISI
Lingua:
GER
Keywords:
acute coronary syndromes; GP IIb/IIIa receptor antagonists;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Haase, KK Univ Heidelberg, Klinikum Mannheim gGmbH, Med Klin 2, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany Univ Heidelberg Theodor Kutzer Ufer 1-3 Mannheim Germany D-68167
Citazione:
K.K. Haase e W. Koenig, "Clinical benefit of glycoprotein IIb/IIIa receptor antagonists in patientswith acute coronary syndrome", PERFUSION, 14(2), 2001, pp. 56-60

Abstract

Acute coronary syndromes are one of the commonest diseases requiring hospital admission in Western countries with an estimated incidence of 2 per 1000 admissions annually. New strategies for the inhibition of platelets focuson the blockade of the platelet surface membrane glycoprotein IIb/IIIa receptor, which binds to circulating fibrinogen or von Willebrand factor, and crosslinks platelets as the final common pathway of platelet aggregation. Over 30.000 patients have been evaluated in several, large-scale, placebo-controlled trials using various GP IIb/IIIa antagonists during the course of an acute coronary syndrome. The clinical benefit achieved by the administration of these compounds occurred early during therapy and persisted over a period of months and years. Based on these findings, the administration of GP IIb/IIIa antagonists is recommended in all patients with severe or prolonged chest pain and particularly in patients with an elevated cardiac troponin T or troponin I. The treatment benefit achieved with this regimen was particularly apparent in those patients, in whom early coronary revascularization was performed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 20:20:40